Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 2/20 | 0.62 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.47 |
| ▸ | SPR | P35270 | 5/20 | 0.42 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.39 |
| ▸ | VNN1 | O95497 | 2/20 | 0.38 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.38 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.37 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27866771 | 0.91 | HSD11B1 (0.53) | HSD11B1USP30SPRKDM4DPDE10A | |
| SCHEMBL26666679 | 0.91 | HSD11B1 (0.54) | HSD11B1USP30SPRKDM4D | |
| SCHEMBL5242729 | 0.88 | HSD11B1 (0.62) | HSD11B1USP30SPRKDM4DPDE10A | |
| SCHEMBL21285788 | 0.88 | HSD11B1 (0.69) | HSD11B1USP30SPRDDB1CRBN | |
| SCHEMBL13738053 | 0.88 | HSD11B1 (0.62) | HSD11B1USP30SPRKDM4DPDE10A | |
| SCHEMBL18711272 | 0.87 | HSD11B1 (0.50) | HSD11B1USP30SPRKDM4DDDB1 | |
| SCHEMBL10223184 | 0.87 | HSD11B1 (0.60) | HSD11B1USP30SPRKDM4DPDE10A | |
| SCHEMBL18701755 | 0.87 | HSD11B1 (0.60) | HSD11B1USP30SPRKDM4DPDE10A | |
| SCHEMBL15721134 | 0.85 | HSD11B1 (0.59) | HSD11B1USP30SPRKDM4DPDE10A | |
| SCHEMBL15721133 | 0.85 | HSD11B1 (0.59) | HSD11B1USP30SPRKDM4DPDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3356345-B1 | HETEROARYL DERIVATIVES AS SEPIAPTERIN REDUCTASE INHIBITORS | MAX PLANCK GESELLSCHAFT (DE) | 2023-11-08 | — | — | EP | disclosed |
| CN-109897038-B | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | 艾伯维爱尔兰无限公司 | 2022-04-05 | — | — | CN | disclosed |
| CN-108175749-B | Melt-extruded solid dispersions containing apoptosis-inducing agents | 艾伯维爱尔兰无限公司 | 2021-09-10 | — | — | CN | disclosed |
| US-20170096435-A1 | SEPIAPTERIN REDUCTASE INHIBITORS | MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2017-04-06 | — | — | US | disclosed |
| CN-103282025-A | Melt-extruded solid dispersions containing apoptosis-inducing agents | ABBVIE INC | 2013-09-04 | — | — | CN | disclosed |
| CN-102448959-A | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBOTT LAB | 2012-05-09 | — | — | CN | disclosed |
| US-7737166-B2 | Antifungal bicyclic hetero ring compounds | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-06-15 | — | — | US | disclosed |
| US-20090143353-A1 | such as 2-tert-Butyl-7-[(3S)-3-(dimethylamino)pyrrolidin-1-yl]-5-methyl-6-phenyl-1,3-benzoxazole-4-carbonitrile hydrochloride, a 1,6-beta-glucan synthetase inhibitor having potent growth inhibition, used treating a fungal infections; fungicides | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-06-04 | — | — | US | disclosed |
| EP-1932837-A1 | BICYCLO HETEROCYCLIC COMPOUND HAVING ANTIFUNGAL ACTION | Daiichi Sankyo Company, Limited (JP) | 2008-06-18 | — | — | EP | disclosed |
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | PHARMACIA CORPORATION | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143353-A1 | such as 2-tert-Butyl-7-[(3S)-3-(dimethylamino)pyrrolidin-1-yl]-5-methyl-6-phenyl-1,3-benzoxazole-4-carbonitrile hydrochloride, a 1,6-beta-glucan synthetase inhibitor having potent growth inhibition, used treating a fungal infections; fungicides | CTPS1, TPP1, STS | HSD11B1 1280/4885USP30 3420/4885SPR 2296/4885 |
| US-20170096435-A1 | SEPIAPTERIN REDUCTASE INHIBITORS | SPR, QDPR, SRR | HSD11B1 375/4885USP30 3314/4885SPR 1/4885 |
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | MAPK1, MAPK3, MAPK4 | HSD11B1 3077/4885USP30 579/4885SPR 3076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.